Home/Pipeline/Intranasal COVID-19 Vaccine

Intranasal COVID-19 Vaccine

COVID-19

PreclinicalActive

Key Facts

Indication

COVID-19

Phase

Preclinical

Status

Active

Company

BioComo

About BioComo

Japanese biotech developing intranasal spray vaccines using a proprietary human parainfluenza virus vector platform for respiratory infections and cancer.

View full company profile

Therapeutic Areas

Infectious Disease Oncology

Other COVID-19 Drugs

Drug	Company	Phase	Status
COVID-19 Severity Prediction Test	Age Labs	Development	Active
PanCytoVir™ (oral probenecid)	TrippBio	Phase 2	Active
ARCoV	Abogen	Approved (EUA)	Commercial/Authorized
OT-101	Sapu BioScience	Clinical Trial (Phase not specified)	Active
COVID-19 Vaccine (Inactivated)	Kangtai Biological Products	Approved	Commercial/Emergency Use
COVID-19 Vaccine (Adenovirus Vector)	Kangtai Biological Products	Approved	Commercial/Emergency Use
Idylla SARS-CoV-2 Test	Biocartis	Approved	CE-IVD
Adjuvanted Cell-Based COVID-19 Vaccine	CSL Seqirus	Marketed	Commercial (region-dependent)
Sequential Dialysis Technique	Halberd	Discovery	Conceptual / Dormant
Amubarvimab + Romlusevimab (BRII-196/BRII-198)	Brii Biosciences	Approved	Commercial (China)
COVID-19 Vaccine Testing (for AstraZeneca)	Advaxia Biologics	Approved	Active
COVID-19 Vaccine Clinical Batches	Advaxia Biologics	Clinical	Active